A Law Firm Representing Injured People
Enter your phone number (no dashes) and we'll call you now.
1-866-9-4EDGAR
Toll Free 24/7 (1-866-943-3427)

Other posts in Antidepressant

May
2007
Antidepressant Suicide Warning for Young Adults
Feb
2007
Youth suicides on the rise
Dec
2006
Antidepressants may get new labels
Dec
2006
Younger antidepressant users have more suicidal thoughts
Jul
2006
Antidepressants and migraine drugs may be a dangerous mix
Edgar Snyder & Associates Free Legal Consulation Edgar Snyder & Associates Free Legal Consulation

Fill out this form to get a free legal evaluation. A legal expert will examine your situation to see if you have a case.

Personal Information

First Name

Last Name

City

State

ZIP

Phone #

Email

Age

Is an attorney currently handling this case?

Yes
No

Injury Information

Briefly describe your injuries

Privacy Policy & Legal Disclaimer

Antidepressant Suicide Warning for Young Adults

May 2007

Young adults experience suicide risk Attention anyone 18 to 24 taking Prozac, Paxil, or any antidepressant drugs – beware of the dangerous risks of suicidal thoughts and behaviors during initial treatment. The Food and Drug Administration (FDA) has proposed that every variety of antidepressant medication update their current black box labels to include warning of heightened risk of suicide in young adults beginning treatment.

Using post-marketing tracking research, the federal agency decided that the 2005 label changes noting tendency towards suicide for children must now be accompanied by the proposed warning for young adults. Risk of suicide rises in the first few months of antidepressant treatment for patients between the ages of 18 and 24, but does not present an increased risk for those above 24.

All antidepressant medication has been targeted for label changes:

  • Anafranil (clomipramine)
  • Asendin (amoxapine)
  • Aventyl (nortriptyline)
  • Celexa (citalopram hydrobromide)
  • Cymbalta (duloxetine)
  • Desyrel (trazodone HCl)
  • Elavil (amitriptyline)
  • Effexor (venlafaxine HCl)
  • Emsam (selegiline)
  • Etrafon (perphenazine/amitriptyline)
  • fluvoxamine maleate
  • Lexapro (escitalopram hydrobromide)
  • Limbitrol (chlordiazepoxide/amitriptyline)
  • Ludiomil (maprotiline)
  • Marplan (isocarboxazid)
  • Nardil (phenelzine sulfate)
  • nefazodone HCl
  • Norpramin (desipramine HCl)
  • Pamelor (nortriptyline)
  • Parnate (tranylcypromine sulfate)
  • Paxil (paroxetine HCl)
  • Pexeva (paroxetine mesylate)
  • Prozac (fluoxetine HCl)
  • Remeron (mirtazapine)
  • Sarafem (fluoxetine HCl)
  • Seroquel (quetiapine)
  • Sinequan (doxepin)
  • Surmontil (trimipramine)
  • Symbyax (olanzapine/fluoxetine)
  • Tofranil (imipramine)
  • Tofranil-PM (imipramine pamoate)
  • Triavil (perphenazine/amitriptyline)
  • Vivactil (protriptyline)
  • Wellbutrin (bupropion HCl)
  • Zoloft (sertraline HCl)
  • Zyban (bupropion HCl)

The manufacturers of antidepressant drugs now have 30 days to submit revised labels and Medication Guides to reflect the updated warning.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation may involve co-counsel.

Source: "FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications." FDA Press Release. May 2, 2007.
Awards

Edgar Snyder & Associates has received some of the highest distinctions awarded to attorneys & law firms. Click a logo to learn more: